Treppel v. Biovail Corp.

249 F.R.D. 111, 2008 U.S. Dist. LEXIS 25867, 2008 WL 866594
CourtDistrict Court, S.D. New York
DecidedApril 2, 2008
DocketNo. 03 Civ. 3002(PKL)(JCF)
StatusPublished
Cited by50 cases

This text of 249 F.R.D. 111 (Treppel v. Biovail Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Treppel v. Biovail Corp., 249 F.R.D. 111, 2008 U.S. Dist. LEXIS 25867, 2008 WL 866594 (S.D.N.Y. 2008).

Opinion

MEMORANDUM AND ORDER

JAMES C. FRANCIS IV, United States Magistrate Judge.

As discussed in several prior decisions, this case concerns a vendetta between plaintiff Jerry I. Treppel, a securities analyst who claims that his career was destroyed by a smear campaign engineered by the defendants, and Eugene N. Melnyk, the Chairman and Chief Executive Officer of Biovail Corporation (“Biovail”), who contends that Mr. Treppel published false information that defamed him and caused the stock of Biovail to plunge. After two rounds of motions to dismiss, the plaintiffs surviving claims include defamation, tortious interference with prospective economic advantage, and civil conspiracy. Now that the parties have completed discovery, the plaintiff moves to compel the production of additional electronically stored information (“ESI”) and to sanction the defendants for failing to preserve evidence. For the reasons described below, the motion is granted in part and denied in part. Background1

Prior to the events that gave rise to this litigation, Mr. Treppel was a securities research analyst who reported on the healthcare and pharmaceutical industries for Banc of America Securities (“BAS”) and other securities firms. Two of the companies that he routinely analyzed were Biovail and its competitor, Andrx Corporation (“Andrx”). In 1993, Mr. Treppel acquired 24,000 shares of Andrx stock. He claims that he fulfilled all reporting obligations with respect to that investment and held the stock in a managed account so that he could not direct or control its trading.

In October 2000 and again in January 2002, Mr. Treppel downgraded his recommendation for Biovail. This resulted in substantial declines in its stock value. According to Mr. Treppel, Biovail responded by retaining media consultants Michael S. Sitrick and Sitrick and Company to engineer a campaign to sully his reputation as an analyst. As part of this campaign, the defendants obtained Mr. Treppel’s personal account statements by taking allegedly improper discovery of BAS, a nonparty to this litigation, in a lawsuit in Florida.

On April 29, 2002, Mr. Treppel issued a report and made public comments that were critical of Biovail and its management; he also further downgraded his recommendation for the company. Immediately thereafter, Biovail’s stock declined in value by more than twenty percent, resulting in substantial personal losses for Mr. Melnyk, who owned eighteen percent of the company’s outstanding shares. There then followed a series of conference calls between Biovail executives, including Mr. Melnyk, and executives from BAS; the most significant appears to have taken place on May 13, 2002. (Notes from teleconference call of May 13, 2002, attached as Exh. A to Affirmation of James A. Batson dated Feb. 5, 2008 (“Batson Aff.”)). After Biovail executives were unable to persuade BAS to retract the April 2000 report, Mr. Treppel alleges that the defendants retaliated against him by providing his personal account statements to the Wall Street Journal and falsely telling the press that he had traded Andrx shares to coincide with the issuance of his recommendations, thus illegally profiting from his own reports. The information appeared in a Wall Street Journal article shortly thereafter. (Laurie P. Cohen & Randall Smith “Buy Analyst Profits on Andrx Trades,” Wall St. J., May 16, 2002, at C4, attached as Exh. C to Batson Aff.). Ac[115]*115cording to Mr. Treppel, the defendants made some eleven defamatory statements about him, including assertions that he was biased against Biovail because of a conflict of interest in relation to Andrx, that he had concealed his stock holdings in Andrx while reporting on Biovail, and that he had engaged in unlawful conduct by purportedly profiting from his recommendations concerning both Andrx and Biovail.

As a result of these statements having been circulated in the press, Mr. Treppel was investigated by the New York State Attorney General’s Office, the Securities and Exchange Commission, and the National Association of Securities Dealers. In addition, Mr. Treppel alleges that in May 2002 the defendants pressured BAS into placing him on leave and ultimately forcing him to resign.

Mr. Treppel commenced this action on April 29, 2003. He did not effect service of the initial complaint, however, and instead served an amended complaint in August 2003. Nonetheless, Kenneth Cancellara, Biovail’s General Counsel, testified that “shortly after” Biovail learned that Mr. Treppel had instituted an action, presumably sometime in May 2003, he orally instructed Mr. Melnyk and Kenneth Howling (Biovail’s Vice President of Finance and Corporate Affairs at the time) to preserve relevant information. (Excerpts of Deposition of Kenneth Cancellara dated Sept. 28, 2007 (“Cancellara Dep.”), attached as Exh. 1 to Declaration of Shalom Doron dated Feb. 21, 2008 (“Doron Decl.”) and as Exh. B to Affirmation of Christine A. Palmieri dated March 3, 2008 (“Palmieri Aff.”), at 288).2 No instructions were issued in writing, nor did Mr. Cancellara follow up with either Mr. Melnyk or Mr. Howling as to what actions they had taken to preserve relevant materials. (Cancellara Dep. at 288-89). Mr. Howling recalled being instructed to preserve relevant documents, but could not remember with any specificity when that instruction was given. (Excerpts of Deposition of Kenneth Howling dated March 7, 2007 (“Howling Dep.”), attached as Exh. 2 to Doron Deck, at 23). In response to Mr. Cancellara’s instruction, Mr. Howling directed his staff to preserve documents related to the Treppel litigation. (Howling Dep. at 23-25). Mr. Melnyk did not recall the instruction from Mr. Cancellara at all. Rather, he remembered preserving relevant documents upon learning of an investigation by the Ontario Securities Commission, though he could not recall when that investigation began. (Excerpts of Deposition of Eugene N. Melnyk dated Sept. 6, 2007 (“Melnyk Dep.”), attached as Exh. K to Batson Aff. and as Exh. 3 to Doron Deck, at 74-77). Mr. Melnyk also remembered being advised in writing in December 2003 to preserve relevant email; he had already begun to do so by that time. (Melnyk Dep. at 92-93, 102-05). Mr. Cancellara also took steps to preserve relevant files on his own system, namely by “not deleting] anything.” (Cancellara Dep. at 293). No instructions were given to Biovail’s Information Technology (“IT”) department prior to December 2003. (Cancellara Dep. at 299-300; Excerpts of Deposition of Tien Nguyen dated July 25, 2007 (“Nguyen Dep.”), attached as Exh. F to Batson Aff. and as Exh. 4 to Doron Deck, at 19).

On December 3, 2003, Mr. Treppel’s counsel sent a letter to counsel for Biovail demanding that it preserve all information, including ESI, relevant to the claims and defenses in the action. (Letter of R. Scott Garley dated Dec. 3, 2003, attached as Exh. D. to Batson Aff.). At this point, Mr. Cancellara apparently repeated his instructions to Mr. Melnyk and Mr. Howling, and learned that they had “taken steps to preserve.” (Cancellara Dep. at 288, 290). However, Mr. Cancellara also testified that he “wasn’t involved in issuing at that stage any notice to anybody personally.” (Cancellara Dep. at 295). At around that time, Biovail also first preserved a backup of its computer system by removing one of the daily backup tapes for each of its servers from the regular rotation.3 (Cancellara Dep. at [116]*116299).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
249 F.R.D. 111, 2008 U.S. Dist. LEXIS 25867, 2008 WL 866594, Counsel Stack Legal Research, https://law.counselstack.com/opinion/treppel-v-biovail-corp-nysd-2008.